Investigation of the promising repurposed, computational, and anticancer candidates to co-deliver with cabazitaxel for hormonal-resistance prostate cancer

The novel antimicrotubular taxane called cabazitaxel was developed to avoid the primary mechanism of resistance for docetaxel, the first-line treatment for patients with hormone-resistant prostate cancer (HRPC). However, its ability to increase the survival rate for HRPC is limited to a few months, and cabazitaxel-resistant prostate cancer was also developed. Consequently, this review aims to assess the repurposing, computational, and anticancer candidates that may be used in conjunction with cabazitaxel to improve its antiproliferative efficacy against prostate cancer. This work reveals that there are no additional benefits when combining cabazitaxel with chemotherapies with similar mechanisms of action, such as docetaxel. Diethylstilbestrol and ketoconazole were not recommended for use with cabazitaxel since they had modest anticancer effects and caused lethal toxicity. Computational studies have demonstrated that HRPC gene inhibitors may have promising anticancer activity against prostate cancer. Additionally, loading these combinations in transferrin-targeted nano-sized vesicles can significantly enhance their anticancer efficacy.